Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Singtel likely to sell stake worth Rs 8,500 crore in Bharti Airtel via block deal: Report
Singtel plans to offload nearly 5 crore Bharti Airtel shares via block deals worth ₹8,500 crore at a 3.6% discount. Bharti Airtel recently reported a
May 15, 2025